Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Topiramate for Migraine Prevention in Pediatric Subjects 12 to 17 Years of Age

D. Lewis; P. Winner; J. Saper; S. Ness; E. Polverejan; S. Wang; C. L. Kurland; J. Nye; E. Yuen; M. Eerdekens; L. Ford

doi:10.1542/peds.2008-0642

Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Topiramate for Migraine Prevention in Pediatric Subjects 12 to 17 Years of Age

PEDIATRICS ◽

10.1542/peds.2008-0642 ◽

2009 ◽

Vol 123 (3) ◽

pp. 924-934 ◽

Cited By ~ 91

Author(s):

D. Lewis ◽

P. Winner ◽

J. Saper ◽

S. Ness ◽

E. Polverejan ◽

...

Keyword(s):

Controlled Study ◽

Migraine Prevention ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab in migraine prevention: primary results of the arise trial

Journal of Neurology Neurosurgery & Psychiatry ◽

10.1136/jnnp-2017-316074.63 ◽

2017 ◽

Vol 88 (5) ◽

pp. e1.63-e1 ◽

Cited By ~ 8

Author(s):

David Dodick ◽

Messoud Ashina ◽

David Kudrow ◽

Michel Lanteri-Minet ◽

Vera Osipova ◽

...

Keyword(s):

Controlled Study ◽

Migraine Prevention ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab (amg 334) in migraine prevention: primary results of the strive trial

Journal of Neurology Neurosurgery & Psychiatry ◽

10.1136/jnnp-2017-316074.62 ◽

2017 ◽

Vol 88 (5) ◽

pp. e1.62-e1 ◽

Cited By ~ 5

Author(s):

Peter J Goadsby ◽

Uwe Reuter ◽

Jo Bonner ◽

Gregor Broessner ◽

Yngve Hallstrom ◽

...

Keyword(s):

Controlled Study ◽

Migraine Prevention ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age

Neuropediatrics ◽

10.1055/s-2008-1079524 ◽

2008 ◽

Vol 39 (01) ◽

Author(s):

DW Lewis ◽

P Winner ◽

J Saper ◽

S Ness ◽

E Polverejan ◽

...

Keyword(s):

Controlled Study ◽

Migraine Prevention ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double‐blind, placebo‐controlled study

Headache The Journal of Head and Face Pain ◽

10.1111/head.14138 ◽

2021 ◽

Author(s):

Takao Takeshima ◽

Fumihiko Sakai ◽

Koichi Hirata ◽

Noboru Imai ◽

Yasuhiko Matsumori ◽

...

Keyword(s):

Japanese Patients ◽

Controlled Study ◽

Migraine Prevention ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Mo1540 THE EFFICACY AND SAFETY OF GCWB104 (FLOS LONICERA EXTRACT) IN FUNCTIONAL DYSPEPSIA: A SINGLE-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

Gastroenterology ◽

10.1016/s0016-5085(20)32906-1 ◽

2020 ◽

Vol 158 (6) ◽

pp. S-887-S-888

Author(s):

Nayoung Kim ◽

Yonghoon Choi ◽

Dong Ho Lee

Keyword(s):

Functional Dyspepsia ◽

Controlled Study ◽

Efficacy And Safety ◽

Single Center ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725732407.793547378 ◽

2018 ◽

Author(s):

Maria Laura Bertolaccini

Keyword(s):

Systemic Lupus Erythematosus ◽

Monoclonal Antibody ◽

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

B Cell Activating Factor

Download Full-text

Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of AS-013, a Prostaglandin E1Prodrug, in Patients With Intermittent Claudication

Circulation ◽

10.1161/01.cir.95.9.2298 ◽

1997 ◽

Vol 95 (9) ◽

pp. 2298-2302 ◽

Cited By ~ 59

Author(s):

J.J.F. Belch ◽

P.R.F. Bell ◽

D. Creissen ◽

J.A. Dormandy ◽

R.C. Kester ◽

...

Keyword(s):

Intermittent Claudication ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Statement of Retraction: Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study

International Journal of Psychiatry in Clinical Practice ◽

10.1080/13651501.2021.1950437 ◽

2021 ◽

pp. 1-1

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Controlled Study ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

The efficacy and safety of dupilumab in Chinese patients with moderate‐to‐severe atopic dermatitis: a randomized, double‐blind, placebo‐controlled study

British Journal of Dermatology ◽

10.1111/bjd.20690 ◽

2021 ◽

Author(s):

Y. Zhao ◽

L. Wu ◽

Q. Lu ◽

X. Gao ◽

X. Zhu ◽

...

Keyword(s):

Atopic Dermatitis ◽

Chinese Patients ◽

Controlled Study ◽

Severe Atopic Dermatitis ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis

Arthritis & Rheumatology ◽

10.1002/art.39722 ◽

2016 ◽

Vol 68 (9) ◽

pp. 2174-2183 ◽

Cited By ~ 55

Author(s):

Brad H. Rovin ◽

Ronald F. van Vollenhoven ◽

Cynthia Aranow ◽

Carrie Wagner ◽

Robert Gordon ◽

...

Keyword(s):

Lupus Nephritis ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Active Lupus Nephritis ◽

Active Lupus

Download Full-text